Free Trial
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:LNTH

Lantheus Q2 2026 Earnings Results & Report

Lantheus logo
$100.02 -0.09 (-0.09%)
Closing price 04:00 PM Eastern
Extended Trading
$100.04 +0.02 (+0.01%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantheus beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 6, 2026. The company reported EPS of $1.55 versus the $1.30 consensus estimate, while revenue of $388.18 million topped the $363.23 million estimate by $24.95 million. Revenue increased 2.7% year over year.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
9:30 AM ET

Lantheus EPS Results

Actual EPS
$1.55
Consensus EPS
$1.30
Beat/Miss
Beat by +$0.25
One Year Ago EPS
$1.57
EPS Beat Rate
4 of last 8 quarters

Lantheus Revenue Results

Actual Revenue
$388.18 million
Expected Revenue
$363.23 million
Beat/Miss
Beat by +$24.95 million
YoY Revenue Growth
+2.70%

Upcoming Earnings

Lantheus' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Q3 2026 Earnings Report

Conference Call Resources

Powered by Quartr

Earnings Documents

Lantheus' Q2 2026 Press ReleasePress Release
(8-K)
Lantheus' Q2 2026 Quarterly reportQuarterly report
(10-Q)

Lantheus Q2 2026 Earnings FAQ

Lantheus (NASDAQ:LNTH) reported earnings of $1.55 per share for Q2 2026, beating the consensus estimate of $1.30. The report was announced on Thursday, August 6, 2026.

Lantheus reported revenue of $388.18 million for Q2 2026, against a consensus estimate of $363.23 million.

Lantheus' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lantheus on the company's earnings history page.

Lantheus Earnings Headlines

Mizuho downgrades Lantheus Holdings to neutral from outperform
October 13 at 2:38 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/mizuho-downgrades-lantheus-holdings-to-neutral-from-outperform/ar-AA2e9orM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Option Care Health, Inc. (Nasdaq – OPCH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX), Sangoma Technologies Corporation (Nasdaq – SANG)
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375711/0/en/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-option-care-health-inc-nasdaq-opch-lantheus-holdings-inc-nasdaq-lnth-marketaxess-holdings-inc-n.html
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
October 13 at 1:00 AM  |  The Oxford Club (Ad)
Lantheus Holdings, Inc. Receives Cms Transitional Pass-Through Status and Permanent Hcpcs Code for Pylarify Truvu
September 30, 2026  |  marketscreener.comM
Lantheus Holdings, Inc. erhält CMS-Status für vorübergehende separate Erstattung und dauerhaften HCPCS-Code für Pylarify TruVu
September 30, 2026  |  de.marketscreener.comD
Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)
September 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3371873/0/en/lantheus-announces-cms-grants-transitional-pass-through-status-for-pylarify-truvu-piflufolastat-f-18.html
See More Lantheus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lantheus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantheus and other key companies, straight to your email.

About Lantheus

Lantheus (NASDAQ:LNTH) (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging. Lantheus also offers radiopharmaceutical products and related imaging solutions used in nuclear medicine and other diagnostic procedures.

Lantheus serves hospitals, imaging centers, clinics and other healthcare providers, primarily in the United States, while also maintaining international commercial and development activities. The company traces its roots to the development and commercialization of medical imaging products and is headquartered in North Billerica, Massachusetts.

View Lantheus Profile
Earnings Tools